Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 33, Issue 11, 2015, Pages 1235-1242

  Yang, Jun J ^a   Landier, Wendy ^b   Yang, Wenjian ^a   Liu, Chengcheng ^a   Hageman, Lindsey ^b   Cheng, Cheng ^a   Pei, Deqing ^a   Chen, Yanjun ^b   Crews, Kristine R ^a   Kornegay, Nancy ^a   Wong, F Lennie ^b   Evans, William E ^a   Pui, Ching Hon ^a   Bhatia, Smita ^b   Relling, Mary V ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE; NUCLEOSIDE DIPHOPHATE LINKED MOIETY X TYPE MOTIF 15 PROTEIN; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; INORGANIC PYROPHOSPHATASE; MTH2 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; AFRICAN; ALLELE; AMERICAN INDIAN; ARTICLE; BLACK PERSON; CAUCASIAN; CHILDHOOD LEUKEMIA; CORRELATION ANALYSIS; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; EAST ASIAN; ETHNIC DIFFERENCE; EUROPEAN; GENE FREQUENCY; GENE LOCUS; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HISPANIC; HOMOZYGOSITY; HUMAN; INDIVIDUALIZATION; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; AGE; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; DOSE CALCULATION; ETHNOLOGY; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HEREDITY; HETEROZYGOTE; HOMOZYGOTE; METABOLISM; PHARMACOGENETICS; PHENOTYPE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME;

6-MERCAPTOPURINE; AGE FACTORS; ANTIMETABOLITES, ANTINEOPLASTIC; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG DOSAGE CALCULATIONS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HEREDITY; HETEROZYGOTE; HISPANIC AMERICANS; HOMOZYGOTE; HUMANS; LINEAR MODELS; PHARMACOGENETICS; PHENOTYPE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; PYROPHOSPHATASES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84927137703     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.4671     Document Type: Article

References (41)

1. Pui CH, Mullighan CG, Evans WE, et al: Pediatric acute lymphoblastic leukemia: Where are we going and how do we get there? Blood 120:1165-1174, 2012
2. Pui CH, Carroll WL, Meshinchi S, et al: Biology, risk stratification, and therapy of pediatric acute leukemias: An update. J Clin Oncol 29:551-565, 2011
3. Hunger SP, Lu X, Devidas M, et al: Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the Children's Oncology Group. J Clin Oncol 30:1663-1669, 2012
4. Koren G, Ferrazini G, Sulh H, et al: Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N Engl J Med 323:17-21, 1990
5. Relling MV, Hancock ML, Boyett JM, et al: Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93:2817-2823, 1999
6. Childhood ALL Collaborative Group: Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: Overview of 42 trials involving 12 000 randomised children. Lancet 347:1783-1788, 1996
7. Toyoda Y, Manabe A, Tsuchida M, et al: Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 18:1508-1516, 2000
8. Schmiegelow K, Schrøder H, Gustafsson G, et al: Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy: Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol 13:345-351, 1995
9. Evans WE, Relling MV: Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 286:487-491, 1999
10. Evans WE, Relling MV: Moving towards individualized medicine with pharmacogenomics. Nature 429:464-468, 2004
11. Giacomini KM, Yee SW, Ratain MJ, et al: Pharmacogenomics and patient care: One size does not fit all. Sci Transl Med 4:153ps18, 2012
12. Relling MV, Gardner EE, Sandborn WJ, et al: Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 89:387-391, 2011
13. Relling MV, Hancock ML, Rivera GK, et al: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91:2001-2008, 1999
14. Relling MV, Pui CH, Cheng C, et al: Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 107:843-844, 2006
15. Evans WE, Hon YY, Bomgaars L, et al: Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 19:2293-2301, 2001
16. Takatsu N, Matsui T, Murakami Y, et al: Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 24:1258-1264, 2009
17. Bhatia S, Landier W, Hageman L, et al: Adherence to oral 6-mercaptopurine in African American and Asian children with acute lymphoblastic leukemia: A Children's Oncology Group study. Blood 124:2345-2353, 2014
18. Kham SK, Soh CK, Liu TC, et al: Thiopurine S-methyltransferase activity in three major Asian populations: A population-based study in Singapore. Eur J Clin Pharmacol 64:373-379, 2008
19. Cooper SC, Ford LT, Berg JD, et al: Ethnic variation of thiopurine S-methyltransferase activity: A large, prospective population study. Pharmacogenomics 9:303-309, 2008
20. Bhatia S, Landier W, Shangguan M, et al: Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: A report from the Children's Oncology Group. J Clin Oncol 30:2094-2101, 2012
21. Pui CH, Campana D, Pei D, et al: Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 360:2730-2741, 2009
22. Price AL, Patterson NJ, Plenge RM, et al: Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38:904-909, 2006
23. Yang JJ, Cheng C, Devidas M, et al: Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet 43:237-241, 2011
24. Pritchard JK, Stephens M, Donnelly P: Inference of population structure using multilocus genotype data. Genetics 155:945-959, 2000
25. Mao X, Bigham AW, Mei R, et al: A genomewide admixture mapping panel for Hispanic/Latino populations. Am J Hum Genet 80:1171-1178, 2007
26. Yates CR, Krynetski EY, Loennechen T, et al: Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126:608-614, 1997
27. McLeod HL, Relling MV, Liu Q, et al: Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 85:1897-1902, 1995
28. Burchenal JH, Murphy ML, Ellison RR, et al: Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood 8:965-999, 1953
29. Pinkel D, Hernandez K, Borella L, et al: Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer 27:247-256, 1971
30. Fotoohi AK, Coulthard SA, Albertioni F: Thiopurines: Factors influencing toxicity and response. Biochem Pharmacol 79:1211-1220, 2010
31. Frandsen TL, Abrahamsson J, Lausen B, et al: Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia: A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. Br J Haematol 155:244-247, 2011
32. Schmiegelow K, Björk O, Glomstein A, et al: Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol 21:1332-1339, 2003
33. Lennard, Lilleyman JS, Van Loon J, et al: Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336:225-229, 1990
34. Black AJ, McLeod HL, Capell HA, et al: Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 129:716-718, 1998
35. Hoffman JM, Haidar CE, Wilkinson MR, et al: PG4KDS: A model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet 166C:45-55, 2014
36. Tai HL, Krynetski EY, Schuetz EG, et al: Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT∗3A, TPMT∗2): Mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci U S A 94:6444-6449, 1997
37. Cai JP, Ishibashi T, Takagi Y, et al: Mouse MTH2 protein which prevents mutations caused by 8-oxoguanine nucleotides. Biochem Biophys Res Commun 305:1073-1077, 2003
38. Takagi Y, Setoyama D, Ito R, et al: Human MTH3 (NUDT18) protein hydrolyzes oxidized forms of guanosine and deoxyguanosine diphosphates: Comparison with MTH1 and MTH2. J Biol Chem 287:21541-21549, 2012
39. Yang SK, Hong M, Baek J, et al: A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 46: 1017-1020, 2014
40. Wang S, Lewis CM, Jakobsson M, et al: Genetic variation and population structure in native Americans. PLoS Genet 3:e185, 2007
41. Krishnamurthy P, Schwab M, Takenaka K, et al: Transporter-mediated protection against thiopurineinduced hematopoietic toxicity. Cancer Res 68:4983-4989, 2008